Share Name Share Symbol Market Type Share ISIN Share Description
Dunedin Income Growth Investment Trust Plc LSE:DIG London Ordinary Share GB0003406096 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  4.00 1.59% 256.00 107,692 16:35:13
Bid Price Offer Price High Price Low Price Open Price
251.00 253.00 253.00 250.00 251.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 20.52 18.20 12.08 21.2 381
Last Trade Time Trade Type Trade Size Trade Price Currency
16:46:54 O 14,722 256.00 GBX

Dunedin Income Growth In... (DIG) Latest News (1)

More Dunedin Income Growth In... News
Dunedin Income Growth In... Takeover Rumours

Dunedin Income Growth In... (DIG) Discussions and Chat

Dunedin Income Growth In... (DIG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Dunedin Income Growth In... trades in real-time

Dunedin Income Growth In... (DIG) Top Chat Posts

Dunedin Income Growth In... Daily Update: Dunedin Income Growth Investment Trust Plc is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker DIG. The last closing price for Dunedin Income Growth In... was 252p.
Dunedin Income Growth Investment Trust Plc has a 4 week average price of 250p and a 12 week average price of 247p.
The 1 year high share price is 3,070p while the 1 year low share price is currently 238p.
There are currently 148,784,898 shares in issue and the average daily traded volume is 65,931 shares. The market capitalisation of Dunedin Income Growth Investment Trust Plc is £380,889,338.88.
ec2: Have done well in these but have today also bought some EDIN as I think this trust looks undervalued in comparison to other UK Equity Income Trusts. The depressed EDIN share price owing to the poor performing, but now to be replaced, asset Mgr creates an opportunity to get into a spread of big dividend hitting UK Equities on the cheap when other similar UK trusts are now on very narrow discounts. The 11% disc and 4.5% yield looks compelling. The 1.65 years of income cover in the income reserve also gives an unrivalled level of comfort for future income distributions. Still keeping my DIG for the income as well but they have had a good run. Hoping EDIN will generate capital growth in addition to the income as the discount moves into line with similar trusts.
speedsgh: from Fund Manager's Report in the latest Factsheet to 31/7/2018... The major share price movements within the portfolio were once again due to company specific events. French employee benefit and payments business Edenred increased sharply on the back of a very positive set of interim results, demonstrating the benefit of our overseas positioning in generating diverse and attractive investment opportunities. UK listed small cap life insurer Chesnara rebounded sharply on a broker upgrade that highlighted the significant discount to net assets and the attractive and growing dividend. Not owning Glencore also proved beneficial as the miner was hit by a potential US Department of Justice investigation into its conduct in a number of emerging markets. At a sector level oil companies lagged as hydrocarbon prices fell following a strong run since the start of the year amidst some concerns over rising US output. In contrast tobacco stocks continued to perform strongly, benefiting from solid results and a stronger dollar, partially reversing some of the very significant underperformance of the past twelve months. Pharmaceutical stocks also performed well primarily led by growing investor enthusiasm for AstraZeneca and their attractive revenue profile from new products. Activity remained relatively high as we continued to shift the portfolio towards better quality, higher growth and smaller companies. As a result we introduced new holdings in life sciences company Abcam and financial services provider London Stock Exchange. Both of these are lower yielding investments but offer the prospect of double digit dividend growth for many years ahead. Abcam is a world leading franchise specialising in the manufacture and distribution of antibodies used in scientific research. It has exceptional long–term growth prospects, a strong balance sheet and the potential to significantly increase their distributions to shareholders over time. London Stock Exchange has a very strong position in the provision of exchange, clearing, index and settlement services. This provides high and resilient levels of growth that should translate into attractive levels of dividend growth to its investors. We added further to positions in a number of mid-sized companies including Hansteen which owns a high yielding portfolio of industrial real estate, Assura the provider of primary care facilities across the UK and Aveva the leading design software provider for oil and gas, power and marine industries. At the larger end of the market cap spectrum we also increased our holding further in British American Tobacco, attracted by the elevated yield and resilient growth and National Grid where strong performance in their US assets increasingly underpins the high and steadily growing dividend. We trimmed our position in Experian given a stretched valuation following a significant increase in the share price on the back of positive results. We also exited our relatively small position in Swiss pharmaceutical giant Roche given lacklustre prospects for dividend growth and reduced our holding in HSBC where the growth outlook is also subdued and the yield no longer offers such an attractive premium to that achievable elsewhere. Our approach remains unchanged and we continue to focus on improving the medium term income and capital growth potential of the portfolio while maintaining appropriate diversity and balancing the near term requirements of our relatively high yield. Benefiting from the new combined research capabilities of the firm we have an increasingly full pipeline of attractive potential investments, particularly those focused toward capital and income growth. Finding higher yielding companies that we deem of sufficient quality for long-term investment is more challenging but we continue to evaluate a number of opportunities. All of which should allow us to position the portfolio in an increasingly differentiated manner, while underpinning the dividend policy. Equity markets remain relatively buoyant although there are a number of headwinds developing, particularly around global trade and the increasingly bellicose approach of the US to the implementation of sanctions on countries such as Turkey. As such we see little reason to shift from a conservative focus on higher quality businesses. While significant movements in large benchmark weighted stocks can affect near term relative performance, given changes to the portfolio and sound corporate performance we remain confident in the total return potential for the trust.
Dunedin Income Growth In... share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Dunedin In..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200920 01:34:10